This Week in Peptide Research: Mitochondrial Peptides, a Bone Density Study After Knee Replacement, and a Quiet Week for GLP-1 Trials

Peptide Science Daily reviewed new PubMed listings for its tracked compounds from September 21 through September 27, 2026. It was a quieter week than the past several, with no new phase 3 trial data on GLP-1 or amylin-receptor obesity drugs and no landmark clinical readout. The items that did appear were smaller in scope: two mitochondrial-derived peptide studies in injury models, a prospective clinical study on bone density after knee replacement, and a cluster of case reports, reviews, and one multi-society treatment guideline.

Two papers examined peptides produced inside mitochondria that are thought to help cells cope with stress. In Cytotechnology, a Turkish team exposed human lung epithelial cells to a synthetic viral mimic and then treated them with SHLP2, a small peptide in the same family as humanin. Cells treated with SHLP2 showed less apoptosis, less mitochondrial membrane depolarization, and lower levels of several inflammatory and oxidative stress markers than cells exposed to the viral mimic alone. The authors also ran computer docking simulations predicting that SHLP2 could interact with two stress-response proteins, which they described as hypothesis-generating evidence, not confirmation of a mechanism. They called SHLP2 an early-stage candidate for further study in viral-like lung injury, based on cell-culture data only. Separately, in Chinese Medical Journal, a team reported that MOTS-c, another mitochondrial-derived peptide, helped mediate the protective effect of remote ischemic preconditioning against lung injury caused by interrupted and restored blood flow in mice, acting through a pathway involving the protein NRF2 and increased mitochondrial biogenesis. The paper was published ahead of print without a public abstract detailing the underlying data, so the finding here reflects only what the title itself reports. Humanin and SHLP2 are both investigational, with no FDA, EMA, or TGA approval for any use. MOTS-c is prohibited at all times under the World Anti-Doping Agency's list of prohibited metabolic modulators, with no therapeutic-use exemption available; the mouse study did not address doping-related use.

In JBJS Open Access, a University of Wisconsin-Madison team published a prospective, open-label, 18-month observational study testing whether abaloparatide could prevent the bone loss in the distal femur that has been reported after total knee arthroplasty (TKA). Fifty-eight patients age 55 or older undergoing TKA were enrolled: 29 with clinical osteoporosis received daily abaloparatide starting roughly three months before surgery, and 29 with osteopenia but no fracture history served as an untreated comparison group. At 15 months after surgery, the treated group's distal femur bone mineral density had increased and differed from the untreated group by 4.6% to 7.6% at two measurement sites (p<0.01 at both), while the untreated group's bone density was statistically unchanged from baseline. The treated group also reported greater improvement on a validated knee-function questionnaire, though they started with worse baseline scores. The authors noted their untreated group did not show the femur bone loss after TKA that some prior reports described, and said further study is needed to clarify that effect. Separately, in European Journal of Endocrinology, Spanish clinicians described a 14-year-old boy who developed severe hypocalcemia after total thyroidectomy for Graves' disease that did not respond adequately to high-dose calcium and calcitriol over 16 days. After multidisciplinary review and family consent, he was started on off-label palopegteriparatide, a long-acting PTH(1-34) prodrug related to teriparatide; his serum calcium improved within 48 hours, and calcium and calcitriol were discontinued within 11 days. The authors described this single case as suggesting the drug may be a useful rescue option in selected children with severe, treatment-resistant post-thyroidectomy hypocalcemia, not as evidence from a controlled trial.

Two review papers touched on GLP-1-family drugs without presenting new trial results. In Pituitary, a scoping review compared hypothalamic obesity in pediatric versus adult survivors of craniopharyngioma, a brain tumor whose treatment can damage weight-regulating brain circuits. The review reported that GLP-1 receptor agonists, including exenatide and semaglutide, produced meaningful weight loss in small case series, in one case up to 17% over six months with semaglutide, but noted that randomized trials of these drugs in this population did not meet their primary weight-loss endpoints and that direct pediatric-versus-adult comparisons are lacking. Separately, in the Journal of Diabetes and Metabolic Disorders, a review of inflammatory mechanisms in pancreatic beta-cell dysfunction noted that randomized trials of several drugs, including liraglutide alongside the anti-inflammatory drug anakinra and other non-peptide agents, have reported improvements in glycemic control or beta-cell function measures, while the anti-inflammatory antibody canakinumab did not reduce new-onset diabetes in trials the review cited. The authors said most of these trials measured metabolic outcomes rather than islet inflammation directly, and that regenerative and gene-editing approaches for beta-cell restoration remain experimental.

Several case reports and one guideline update involved octreotide and desmopressin this week. In the American Journal of Case Reports, Japanese clinicians described a 72-year-old man with chylous ascites, a rare complication of pelvic lymph node surgery, that did not resolve with a low-fat diet and continuous octreotide infusion; the leak was eventually controlled only after two rounds of lymphatic embolization and surgery, illustrating how the underlying leak site can shift during treatment. In Case Reports in Endocrinology, clinicians described a preterm infant with a homozygous ABCC8 gene mutation causing congenital hyperinsulinism who was bridged with octreotide before ultimately responding to diazoxide, a response the authors called unusual for that particular mutation. In JCEM Case Reports, Japanese endocrinologists described a pregnant woman whose diabetes insipidus symptoms responded to desmopressin during the third trimester, resolved after delivery, then recurred six months postpartum alongside antibodies linked to autoimmune pituitary inflammation, a pattern the authors said points to an autoimmune cause unmasked by pregnancy rather than the more commonly reported placental cause. Separately, a focused guideline update from the Neurocritical Care Society and the Society of Critical Care Medicine, published in Neurocritical Care, reviewed treatment evidence for antithrombotic-associated intracranial hemorrhage. Among five treatment questions the panel addressed, it said the evidence was insufficient to issue a recommendation for or against giving desmopressin to patients on antiplatelet drugs, one of three questions on which the panel could not make a recommendation.

Two literature reviews on irritable bowel syndrome with constipation (IBS-C) named linaclotide without presenting new clinical data of their own. In Drugs, a review of pediatric IBS-C pharmacotherapy noted that linaclotide is currently the only medication approved by the FDA for this condition in children age 7 and older, while other newer secretagogues approved for adults in the same drug class have little to no pediatric data. A position paper from the Neurogastroenterology and Motility Section of the Israeli Gastroenterology Association, published in the Journal of Clinical Gastroenterology, listed linaclotide among the secretagogues it recommends considering as part of a broader, stepwise approach to adult IBS management that also includes dietary changes, other drug classes, and psychological therapies.

This week's items span two mitochondrial-derived peptide studies in cell and mouse injury models, one prospective clinical study on bone density after knee replacement, a case report of off-label rescue therapy for pediatric hypocalcemia, two reviews touching GLP-1 drugs without new trial data, four case reports or guideline sections involving octreotide and desmopressin, and two IBS-C reviews naming linaclotide. Exenatide, semaglutide, liraglutide, abaloparatide, teriparatide, octreotide, desmopressin, and linaclotide are approved drugs. Humanin and the related peptide SHLP2 remain investigational with no FDA, EMA, or TGA approval, and MOTS-c is WADA-prohibited at all times with no therapeutic-use exemption available. As with all research covered here, these are findings a given study or case report described, not established clinical fact or treatment guidance.